In this article, Gregory Vistnes outlines why Antitrust Agencies care about clinical integration, an issue that might seem primarily an issue of concern to the healthcare community and not antitrust enforcers, and how the agencies typically evaluate the competitive significance of clinical integration.
Aggregate royalty for cellular SEPs in recent court decisions
This academic paper, “Aggregate Royalty for Cellular SEPs in Recent Court Decisions,” published in GRUR Patent by CRA Competition experts Nadia Soboleva and...